Scientific deep-dive
GLP-1 Drugs and Eating Disorders: The 2026 Expert Consensus Explained
A 45-member panel in World Psychiatry advises screening before GLP-1 treatment and generally avoiding it in active eating disorders, particularly restrictive ones. Here is what it recommends, how thin the evidence is, and what it leaves out.
Screen first, and generally avoid these drugs in active eating disorders, particularly restrictive illness: that is the core of a 2026 consensus in World Psychiatry, where a 45-member panel advised checking for current and past eating disorders before anyone starts a GLP-1 drug[1]. Its statements needed at least 70% agreement and averaged 91.7%, yet the same paper describes the evidence as “limited and inconsistent”[1]. Read it as structured expert judgment for a prescribing conversation. It does not measure how often GLP-1 drugs cause or worsen an eating disorder.
About this article
The consensus covers eating disorders, not psychiatry as a whole, so it says nothing direct about depression, bipolar disorder, or schizophrenia. This summary rests on the paper’s published abstract, which does not reproduce each statement or name a screening questionnaire. Later sections add separate evidence on other psychiatric conditions.
What the panel recommends
The authors used a modified three-round Delphi process, a structured way of polling experts until positions settle. Panel members worked in diabetes, obesity, or eating disorders, and the group included people with lived experience of an eating disorder, GLP-1 use, or both[1]. The positions below are paraphrased from the abstract[1].
| Situation | Panel position |
|---|---|
| Anyone about to start a GLP-1 | Screen for current and past eating disorders first, using a brief, psychometrically validated questionnaire |
| Active anorexia nervosa or atypical anorexia nervosa | Generally avoid |
| Active bulimia nervosa with marked dietary restraint and/or significant weight suppression | Generally avoid |
| Past history of those eating disorders | Proceed cautiously |
| People on treatment | Monitor eating disorder symptoms routinely, with intensity set by risk level |
| Eating disorder present and a GLP-1 prescribed | Offer evidence-based psychotherapy alongside the drug |
| Binge eating disorder | Trials of safety, efficacy and psychological outcomes are a named research priority; the abstract’s caution about active eating disorders does not exempt it |
The panel also called for standardized education materials for patients and clinicians. Its research agenda asks for long-term studies comparing eating disorder incidence, risk factors, and outcomes in GLP-1 users and non-users, plus regulatory studies and policies on prescribing safety[1]. That request is itself informative: those comparisons are what would turn a precaution into a measured risk.
How strong the evidence underneath it is
Thin. A separate 2026 paper by clinicians working across eating disorders and obesity treatment says the field lacks “robust empirical data” directly examining GLP-1 use and eating disorder risk, and it reasons by analogy from bariatric surgery, where symptoms went under-recognized until standardized screening arrived[7]. A Spotlight article in the International Journal of Eating Disorders argues that current prescribing pathways often lack systematic screening, and it proposes screening before and during treatment; its author states that it does not provide a systematic review[8]. Volkow and Xu’s scoping review of pharmacoepidemiology likewise concludes that further surveillance is needed to assess potential risks for anorexia[3].
One longitudinal online study of US women adds a piece. Higher eating disorder psychopathology at baseline was associated with greater odds of using GLP-1 medications six months later, after controlling for baseline medication or supplement use and BMI[6]. That points to who may seek these drugs. It cannot show that the drugs caused any symptoms, and it relies on questionnaire data.
Binge eating is where the picture splits
The worry about restriction sits beside early signals of benefit, a tension our review of GLP-1 drugs and binge eating takes up in more depth. A 2026 systematic review found 12 studies of liraglutide, semaglutide, and dulaglutide, with samples generally under 75 people. Binge eating measures improved consistently and no new psychiatric safety concerns were identified, but small samples, mixed methods, and short follow-up limit the conclusion[5]. In a broader meta-analysis, liraglutide reduced binge frequency against placebo (mean difference -1.28, 95% CI -1.67 to -0.89), within a body of evidence the authors rate as largely low to very low certainty[4].
Volkow and Xu list binge eating disorder and bulimia nervosa among the areas with the strongest emerging pharmacoepidemiologic evidence of benefit, while saying randomized trials are needed to determine whether those associations represent mechanistic effects[3]. That does not contradict the consensus, whose avoid advice names bulimia with marked restraint or significant weight suppression, but it does show how much rests on telling subtypes apart. A review of registered trials counted only one ongoing randomized trial in binge eating disorder (105 planned participants) with a psychiatric or behavioral primary outcome, as of a September 2026 search[9].
A second consensus points the same way
A joint EASO, EFAD, and ECPO statement in Lancet Diabetes & Endocrinology, written from the obesity and nutrition side, recommends psychological screening with integrated support where needed. It flags shifts in food reward, coping, and social connection during treatment, and it wants shared decisions on starting, delaying, pausing, or stopping that weigh the risks of treating against the risks of not treating[2]. That framing matters, since leaving obesity untreated carries its own physical and psychological risks. The authors’ declarations include advisory or educational work for Novo Nordisk and Eli Lilly[2].
What the consensus leaves out
Depression and suicidality
Volkow and Xu report that pharmacovigilance and health-record studies did not support the early concern linking GLP-1 drugs to suicidality[3], a history covered in our article on the FDA and EMA suicidality reviews. In the meta-analysis of neuropsychiatric outcomes, randomized trials showed a pooled suicidality risk ratio of 1.13 (95% CI 0.53 to 2.41) and active-comparator studies a hazard ratio of 0.96 (95% CI 0.81 to 1.15), with no associations observed for depression or anxiety. The authors call their findings hypothesis-generating, and some declare industry ties[4].
Schizophrenia
The evidence here concerns metabolic health, not psychiatric symptoms. In Danish registers, 3,042 people with schizophrenia started a GLP-1 drug. Among those starting for diabetes, HbA1c, LDL, and triglycerides fell 11.4%, 6.2%, and 14.8%; among those starting for overweight, the falls were 3.4%, 4.9%, and 12.7%[10]. This is a before-and-after time-series design without a randomized control. Six registered schizophrenia-spectrum trials also use metabolic rather than psychiatric primary endpoints[9]. Our review of the clozapine and olanzapine trials covers antipsychotic weight gain.
Addiction
Addiction dominates the pipeline: 29 of 34 ongoing randomized trials concern addiction or tobacco use, half of the 34 test a GLP-1-containing co-agonist, and development outside addiction is mostly one manufacturer’s program, which the reviewers say is proceeding without a positive randomized result in any psychiatric indication. Both reviewers declare industry consulting, speaking or grant ties[9]. In a phase 2 trial of 50 people with moderate to severe alcohol use disorder, oral semaglutide (3 mg/day for 4 weeks, then 7 mg/day for 4 weeks) missed the primary outcome of laboratory cue-elicited craving at week 6 and did not significantly reduce drinks per day, though it did reduce heavy drinking days (b = -0.580, 95% CI -1.012 to -0.148)[11]. Nothing in that record yet amounts to a consensus recommendation for treating a psychiatric condition with these drugs.
What to raise with a prescriber
- Your full eating history, including the past. The consensus treats a past eating disorder as a reason for caution, not only a current one[1]. Fasting, purging, laxative use, and compulsive exercise are worth naming even if never diagnosed.
- How you will be screened. If an intake form or a telehealth visit does not ask, bring it up yourself. The consensus advises a validated questionnaire, not a passing question[1].
- Who will watch for change, and how often. Monitoring intensity should match risk[1]. Agree in advance on what would prompt a pause.
- Whether therapy runs alongside the drug. For people with an eating disorder who are prescribed a GLP-1, the panel advises offering evidence-based psychotherapy too[1].
- Your psychiatric medications and diagnoses. This consensus does not address them, so your psychiatrist and prescriber need to compare notes directly.
Frequently Asked Questions
References
- 1.Keshen A, Koning E, Allison KC, Amaro A, Bartel S, Belliveau P, et al. Consensus-based clinical and research recommendations for use of glucagon-like peptide-1 receptor agonists in the context of eating disorders: a modified Delphi study. World Psychiatry. 2026. PMID: 42742590.
- 2.Dobbie LJ, Tolvanen L, Alves D, Baker JL, Bez NS, Birney S, et al. Nutritional, functional, and psychological considerations for incretin-based therapies in adults-an EASO, EFAD, and ECPO Consensus Statement. Lancet Diabetes Endocrinol. 2026. PMID: 42419343.
- 3.Volkow ND, Xu R. Glucagon-Like Peptide-1 Receptor Agonists in Psychiatry: A Pharmacoepidemiological Scoping Review. Biol Psychiatry. 2026. PMID: 41932372.
- 4.Choudhury I, Ward JH, Mahesh S, Alam U, Azmi S, Anson M. Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis. Clin Ther. 2026. PMID: 41862354.
- 5.White RT, Henriquez P, Innocent B, Bullers K, Elmaoued A. Incretin-Based Therapies for the Treatment of Binge Eating-A Systematic Review. Pharmacotherapy. 2026. PMID: 41947645.
- 6.Rosenbaum DL. Eating disorder psychopathology relates to weight loss medication and supplement use 6 months later in women. Eat Weight Disord. 2026. PMID: 41790422.
- 7.Herb Neff KM, Dunford A, Goldschmidt AB, Allison KC, Richeson A. Eating Disorder Risk and Screening in Patients Using GLP-1RAs: Lessons Learned From Metabolic and Bariatric Surgery. Int J Eat Disord. 2026. PMID: 42502918.
- 8.Škudar S. Eating Disorders in the GLP-1 Era: A Spotlight on Emerging Clinical Risks, Research Gaps, and Practice Priorities. Int J Eat Disord. 2026. PMID: 42223191.
- 9.Fagiolini A, Cuomo A. Incretin-based therapies in psychiatry: A landscape analysis of ongoing randomized trials registered on ClinicalTrials.gov. J Psychiatr Res. 2026. PMID: 42962407.
- 10.Mikkelsen NB, Ørberg A, Østergaard SD, Rohde C. Metabolic biomarker levels before and after initiation of GLP-1 receptor agonist treatment among individuals with schizophrenia: interrupted time-series analysis. Br J Psychiatry. 2026. PMID: 42922018.
- 11.Schacht JP, Sakai JT, Raymond K, Shelton R. Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial. Am J Psychiatry. 2026. PMID: 42522065.
Related research
GLP-1 for Binge Eating Disorder: Vyvanse Comparison and Stacking Evidence
Vyvanse is the only FDA-approved drug for BED, but GLP-1 receptor agonists show meaningful reduction in binge episodes per published case series. We review the McElroy 2015 / Hudson 2017 Vyvanse trials, the GLP-1 mechanism, and the practical psychiatric pathway.
11 min read
Which Weight-Loss Drug Works Best With Antipsychotics? What the Rankings Show
Five network meta-analyses rank drugs for antipsychotic weight gain, and they name three different leaders. Here is how semaglutide, liraglutide, metformin and topiramate compare, and how far to trust the order.
8 min read
Night Eating Syndrome: Diagnostic Criteria, Treatment and GLP-1 Evidence
Night eating syndrome: the diagnostic criteria, how common it is with obesity, how it differs from binge eating disorder and sleep-related eating disorder, what trials show for sertraline and CBT, and what is and is not known about GLP-1 drugs and evening eating.
10 min read
GLP-1 Drugs and Binge Eating: Treatment Target or Masking Risk?
Binge eating disorder overlaps heavily with the population taking GLP-1 drugs. There is genuine scientific interest in GLP-1 signaling as a treatment target, and a genuine risk of the drug hiding a disorder. Both deserve saying plainly.
7 min read
GLP-1 + Naltrexone for AUD: The Stacking Evidence
Hendershot 2025 JAMA Psychiatry showed semaglutide reduced alcohol craving and heavy-drinking days in adults with AUD. Combining it with naltrexone (50 mg PO or Vivitrol 380 mg IM) is gaining real-world support. We review the trial data and the practical stacking protocol.
12 min read
GLP-1 Drugs and Alcohol Use Disorder: What the Trial Evidence Actually Shows in 2026
Semaglutide's effect on alcohol use disorder has thin trial support so far: three small randomized trials (n=48, 108, and 50). Hendershot 2025 reduced drinks per drinking day but not drinking days. Naltrexone, acamprosate, and disulfiram remain first-line.
13 min read
Where to get semaglutide (Ozempic / Wegovy) safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
From $99/mo
From $139/mo
4-month plan rate
HumeCare+
GLP-1 weight loss with real-time body-composition tracking to protect muscle
Read full review →From $199/mo